MAGELLAN-3

MAGELLAN-3 Study: GLE/PIB + SOF + RBV in patients who failed GLE/PIB

Wyles D. EASL 2018, Abs. PS-040

Anti-HCV
Glecaprevir (ABT-493)
Pibrentasvir (ABT-530)
Sofosbuvir
Ribavirin
Genotype
1
1a
3
Treatment history
PI (NS3)-experienced
NS5A experienced
Cirrhosis
Yes
No

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design


* SURVEYOR-2, ENDURANCE-3, MAGELLAN-1, EXPEDITION-1

  • GLE/PIB: 100/40 mg 3 tablets QD
  • SOF: 400 mg QD
  • RBV: 1000-1200 mg (BID regimen)

Primary endpoint

  • SVR12 (HCV < LLOQ)

Baseline characteristics

Primary Endpoint (SVR12)


* One relapse: genotype 1a, compensated cirrhosis, failed LDV/SOF prior to GLE/PIB

Adverse events and laboratory abnormalities, N (%)


*Not related to study drugs, not leading to drug discontinuation

Summary

  • GLE/PIB + SOF + RBV resulted in 96% SVR12 in patients with previous GLE/PIB virologic failure
    • 100% SVR12 in the 14 patients with genotype 3
  • Treatment was well-tolerated